Gold nanoparticles tested as brain energy boost for MS
NCT ID NCT03993171
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a liquid suspension of gold nanocrystals, called CNM-Au8, in 33 people with relapsing multiple sclerosis. The goal was to see if the treatment could improve energy metabolism in brain cells, measured by a special MRI scan. Participants took the drug by mouth for 12 weeks while continuing their usual MS medication. The study looked at safety and changes in brain chemistry, not directly at symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gold nanocrystals (CNM-Au8)
What this could lead to
If it works, this could point toward a new way to support brain cell energy in multiple sclerosis, potentially slowing disease progression.
What could go wrong
This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The study focused on brain chemistry changes, not direct symptom improvement, and the treatment may not show clear benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Southwestern
Dallas, Texas, 75390, United States